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ABSTRACT
Background: Primary percutaneous coronary intervention 
is currently the preferred method to treat patients with ST-
segment elevation acute myocardial infarction. The no-reflow 
phenomenon, which is the inability to reperfuse a region of 
the myocardium after restoration of patency of a previously 
occluded epicardial coronary artery, is observed in a con-
siderable proportion of these patients. The benefit of IIb/IIIa 
glycoprotein inhibitors, blocking the final common pathway 
of platelet aggregation, has been suggested in studies of acute 
coronary syndromes, but their actual efficacy in the context 
of no-reflow in patients treated with primary percutaneous 
coronary intervention remains unclear. Methods: The aim of 
this multicenter, double-blinded, placebo controlled study is 
to assess the impact of the early administration of the low 
molecular weight glycoprotein IIb/ IIIa inhibitor tirofiban 
on the incidence of no-reflow using angiographic and elec-
trocardiographic methods to determine: (1) the epicardial 
coronary flow, using the TIMI score, and the microcirculatory 
flow, using the MBG score of opacification and myocardial 
flow; (2) the resolution of the ST segment elevation, as the 
final index of the success of reperfusion. Conclusions: If 
the decrease in no-reflow incidence at 90 minutes and 24 
hours after primary percutaneous coronary intervention is 
confirmed, this pilot study should guide the implementation 
of a larger study to investigate the possible impact of the 
systematic inhibition of the final common pathway of platelet 
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RESUMO
A Inibição da Via Final Comum da Agregação 
Plaquetária Reduz o Fenômeno de Não Reperfusão 
Durante a Intervenção Coronária Percutânea 
Primária? Tirofiban no Infarto Agudo do miocárdio e 
a não Reperfusão (TIARA)
Introdução: A intervenção coronária percutânea primária é hoje 
o método preferencial de reperfusão na abordagem de pacientes 
com infarto agudo do miocárdio com supradesnivelamento do 
segmento ST. Em boa parte desses casos, ocorre o fenômeno 
de não reperfusão, que é a incapacidade de se reperfundir 
uma região do miocárdio após o restabelecimento da patência 
de uma artéria coronária epicárdica previamente ocluída. O 
benefício de inibidores da glicoproteína IIb/IIIa, bloqueando a 
via final comum da agregação plaquetária, tem sido sugerido 
em estudos de síndromes coronárias agudas, mas persistem 
pontos obscuros quanto à sua real eficácia, no contexto da não 
reperfusão, em pacientes tratados com intervenção coronária 
percutânea primária. Métodos: Investigação multicêntrica que 
avaliou o impacto da administração precoce do inibidor da 
glicoproteína IIb/IIIa de baixo peso molecular tirofiban, em 
forma duplo-mascarada, controlada por placebo, sobre a ocor-
rência de não reperfusão, empregando métodos angiográficos 
e eletrocardiográfico para documentar (1) os fluxos coronário 
epicárdico, pelo escore TIMI, e microcirculatório, pelo escore 
MBG de opacificação e escoamento miocárdicos; (2) a resolução 
Study Design
Lago et al. 
Tirofiban and No-reflow of STEMI
Rev Bras Cardiol Invasiva. 
2014;22(1):81-6
82
aggregation on the mortality of ST-segment elevation acute 
myocardial infarction patients. 
 
 
 
 
DESCRIPTORS: Myocardial infarction. Percutaneous coronary 
intervention. Myocardial reperfusion. Thrombolytic therapy. 
Treatment outcome.
occurs in cases of complete perfusion (contrast surpasses 
the lesion at the same speed as in adjacent vessels). 
Gradation of the opacification aspect and myocardial 
outflow is indicated by the Myocardial Blush Grade 
(MBG) score: MBG 0 indicates no myocardial opaci-
fication and no myocardial outflow; MBG 1 indicates 
mild opacification and slow myocardial outflow; MBG 
2 corresponds to moderate opacification and somewhat 
increased myocardial outflow, but still lower than that 
observed in other arteries without lesions; MBG 3 in-
dicates normal opacification and myocardial outflow 
comparable to that observed in other arteries without 
lesions.7,8
Through the electrocardiogram (ECG), non-reperfusion 
is inferred by analyzing the ratio of the ST-segment 
elevation before and after treatment and its complete 
resolution (> 70%), which rules out the occurrence 
of NRP. Lower degrees of ST-segment resolution cha-
racterize the occurrence of NRP, and moderate (30% 
to 70%) to severe (< 30%) degrees of reperfusion are 
commonly observed.9,10
These integrated data stratify these patients in 
varying degrees of no-reflow. Angiographically, non-
reperfusion is characterized if epicardial TIMI ≤ 2, or 
when, even in cases of epicardial TIMI = 3, the degree 
of opacification and myocardial outflow by MBG is not 
≥ 2. These aspects as well as diagnostic factors have 
prognostic consequences, as several studies have shown 
that patients with TIMI 3, MBG 2-3, and resolution of 
ST > 70% have a better outcome compared to those 
with TIMI < 3, MBG 0-1, and ST resolution < 70%.10-12
Numerous therapeutic strategies have been used in 
the NRP approach in primary PCI, among which are 
the use of drugs such as inhibitors of the final common 
pathway of platelet aggregation (abciximab, tirofiban, 
and eptifibatide), vasodilators (dinitrates and trinitrates, 
adenosine, verapamil, and sodium nitroprusside), anti-
inflammatory drugs (statins), antithrombotic agents (hepa-
rin and bivalirudin), metabolic inhibitors (nicorandil), 
and mechanical devices, such as distal filter protection 
catheters and thrombus aspirators. These investigations 
P rimary percutaneous coronary intervention (PPCI), usually with stent implant, is considered the preferred reperfusion strategy, due to its association with high 
rates of recanalization of the occluded artery, reduction 
in ischemic myocardial damage progression and, more 
importantly, mortality reduction in ST-segment eleva-
tion myocardial infarction (STEMI).1 However, patency 
restoration of a previously occluded epicardial artery 
is not always accompanied by adequate reperfusion 
of the myocardium that depends on it.2 This no-reflow 
phenomenon (NRP) occurs in a variable proportion of 
patients (5% to 50%) and has negative impact on the 
known benefits of PPCI, namely: (a) early complications 
after myocardial infarction (arrhythmias, pericardial 
effusion, cardiac tamponade, and heart failure); (b) 
adverse left ventricular remodeling; (c) late readmis-
sions for heart failure; (d) increased mortality rate.2,3 
No-reflow is a complex and dynamic process that in-
volves several physiopathological components such as 
distal atherothrombotic embolization, ischemic lesion, 
reperfusion lesion, and intrinsic susceptibility to coronary 
microcirculation combined with the effects of ischemia 
and reperfusion lesion.3,4 This phenomenon may or may 
not be reversible, depending on the net result of the 
functional and/or anatomical abnormalities of coronary 
microcirculation, as well as the therapeutic approach 
used for its prevention and treatment.
It can be diagnosed at different stages by various 
methods, among which are coronary angiography, 
electrocardiography, and noninvasive imaging methods, 
such as myocardial echocardiography with contrast and 
magnetic resonance.5,6
Coronary angiography with contrast is usually used 
to evaluate non-reperfusion during PPCI by gradation of 
the epicardial flow using the Thrombolysis In Myocardial 
Infarction (TIMI) score: TIMI 0 indicates no perfusion 
(without flow after coronary lesion); TIMI1 represents 
minimum perfusion (contrast surpasses the lesion, but 
shows no opacification of the vessel downstream); TIMI 
2 indicates partial perfusion (contrast surpasses the le-
sion and there is opacification in the distal vessel, but 
with slower speed than in the adjacent vessels); TIMI 3 
do supradesnivelamento do segmento ST, como índice final do 
sucesso da reperfusão. Conclusões: Se comprovada redução 
da incidência de não reperfusão tanto 90 minutos como 24 
horas após a intervenção coronária percutânea primária, este 
estudo-piloto, deve nortear a implementação de estudo mais 
abrangente, para investigar o possível impacto do bloqueio.
DESCRITORES: Infarto do miocárdio. Intervenção coronária 
per cutânea. Reperfusão miocárdica. Terapia trombolítica. Re-
sultado do tratamento.
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have reported inconsistent or merely promising results, 
probably due to the fact that the physiopathology of this 
phenomenon is multivariate, with several key elements 
in every clinical situation.3,13-19 In fact, as observed 
in the context of patients with myocardial infarction 
without ST-segment elevation, the use of glycoprotein 
IIb/IIIa inhibitors (GPI IIb/IIIa) in the presence of dual 
platelet therapy with acetylsalicylic acid and clopidogrel 
did not appear to have a beneficial effect in terms of 
reducing severe events, in addition to increasing the 
risk of bleeding.20
Similarly, in STEMI patients, the use of such agents 
that block the final common pathway of platelet ag-
gregation still lacks a solid scientific basis. It should 
also be noted; however, that use of low molecular 
weight GPI IIb/IIIa (eptifibatide and tirofiban) in 
STEMI has increased in recent years, after studies 
that showed encouraging results equivalent to those 
previously obtained with the high molecular weight 
inhibitor abciximab. Additionally, eptifibatide and 
tirofiban have shown, as opportune advantages, both 
faster reversibility of platelet aggregation inhibition 
after cessation of use and lower cost.12-14 
The general use of this antiplatelet agent group 
is class IIa or IIb recommendation in the most recent 
consensuses (American and European) STEMI and PPCI. 
According to the latest American consensus on STEMI, 
GPI IIb/IIIa have a class IIa recommendation, as it is 
considered acceptable to start treatment with abci-
ximab, tirofiban, or eptifibatide as an adjunct therapy 
to PPCI with or without clopidogrel, or for stent im-
plant in patients receiving unfractionated heparin. The 
same consensus recommends, as class IIb, their use in 
situations preceding the interventional cardiology lab, 
(ambulance and emergency rooms) in patients with 
STEMI who will be submitted to PPCI.21-23
In contrast, the latest European consensus on STEMI 
recommends as class IIa the use of GPI IIb/IIIa only as an 
optional therapy in patients with high thrombotic load, 
slow flow, or no flow. In this consensus, the indication 
of GPI IIb/IIIa remained restrictive (only as class IIb) for 
routine use in patients without contraindications and 
using unfractionated heparin. Similarly, the upstream use 
of these drugs, i.e., before the interventional cardiology 
environment, also had class IIb indication in high-risk 
patients referred for PPCI.22
In a recent study, with over 300,000 STEMI patients 
undergoing PPCI, the use of GPI IIb/IIIa was > 70% 
and, coincidentally, the incidence of NRP was very low 
(2.3%), although its diagnosis was performed exclusively 
by the angiographic criterion of TIMI epicardial flow.24
It should be remembered that in early observational 
studies, as well as in recent randomized trials, tirofiban 
showed low rates of complications such as bleeding 
and thrombocytopenia.13
In summary, the administration of GPI IIb/IIIa is 
usually recommended to treat NRP when detected 
angiographically. However, there remain significant 
questions about the true value and significance of its 
early use (before or just at the beginning of the PPCI 
procedure) to prevent the onset of non-reperfusion, 
especially in patients already treated with dual platelet 
inhibition (combined use of acetylsalicylic acid and 
clopidogrel, according to current practice).
METHODS
This will be a multicenter, prospective, randomized, 
double-blinded (during the phases of procedures and 
analysis of results) study, which will include patients 
that will receive tirofiban or placebo infusion intrave-
nously, with a STEMI diagnosis, and who will have 
been referred for PPCI.
The project was approved by the Research Ethics 
Committee of Hospital das Clínicas da Faculdade 
de Medicina de Ribeirão Preto da Universidade de 
São Paulo, process Nº 2,495/2010. Subsequently, 
the approval of the Research Ethics Committee was 
extended to hospitals São Joaquim and Santa Casa, 
both in Franca (SP), and to Instituto do Coração do 
Triângulo Mineiro, in Uberlândia (MG). Patients who 
meet the inclusion criteria will be offered an informed 
consent to be signed by themselves or their legal 
guardians.
Inclusion criteria are: age > 18 years; chest pain > 20 
minutes with ST elevation ≥ 1 mm in two contiguous 
leads, or with presumably new left bundle branch block 
on the electrocardiogram; and period of up to 12 hours 
of symptom onset for the implementation of PPCI.
Exclusion criteria are: cardiogenic shock; myocardial 
infarction in the same territory; hemorrhagic diathesis; 
use of fibrinolytics; coma after brain anoxia; known 
thrombocytopenia or leukopenia; severe liver dysfunc-
tion; severe renal failure (creatinine > 3.0 mg/dL); 
contraindication to the use of aspirin, thienopyridines, 
or heparin; life expectancy < 1 year; major surgery 
< 3 months; stroke < 30 days; history of intracerebral 
disease (aneurysm and arteriovenous malformation); 
severe trauma < 6 weeks; oral anticoagulant use; and 
participation in another research protocol.
During the randomization of these patients and 
before drug administration protocol, routine blood 
tests (complete blood count, full coagulation profile, 
blood glucose, glycated hemoglobin [Hb], creatinine, 
urea, full lipid profile, potassium, sodium, CK–MB, and 
troponin) will be performed.
Lago et al. 
Tirofiban and No-reflow of STEMI
Rev Bras Cardiol Invasiva. 
2014;22(1):81-6
84
The study endpoint will be the diagnosis of NRP, 
sequentially supported by angiographic methods 
(analysis of coronary angiography and PPCI by TIMI 
and MBG scores) and the electrocardiographic method 
(quantitative analysis of ST-segment elevation before 
PPCI, at 90 minutes after PPCI, and 24 hours after 
the procedure).
The following will be recorded in the study database: 
demographic, clinical, and angiographic characteristics; 
and data on the percutaneous therapeutic interven-
tion and its results: age, gender, ethnicity, weight, 
height, body mass index, history of diabetes mellitus, 
arterial hypertension, dyslipidemia, smoking status 
(current; previous – if > 1 month, or never), obesity, 
family history of coronary artery disease, previous 
myocardial infarction, previous percutaneous coronary 
intervention in another artery, previous coronary artery 
bypass graft surgery, current anterior wall infarction, 
previous heart failure, and current heart failure; time 
of symptom to first medical care, symptom to health 
care in this institution, symptom to drug administra-
tion, symptom to diagnostic catheterization, symptom 
to balloon, institutional medical care to balloon, 
diagnostic procedures, therapeutic procedure; prior 
use of aspirin, beta-blockers, angiotensin-converting 
enzyme inhibitors, statins, nitrate, and illicit drug 
use; history of known coronary heart disease; systolic 
blood pressure < 100 mm Hg, heart rate > 100 bpm, 
Killip-Kimball classification, vascular access (radial, 
brachial, and femoral), artery associated with the cur-
rent STEMI (right coronary artery, left circumflex artery, 
left anterior descending artery, and left main coronary 
trunk), probable artery associated with lesions < 50%; 
pre- and post-procedure TIMI flow scores 0, 1, 2, and 
3; MBG 0, 1, 2, and 3; type of lesion A, B, or C; 
presence of single-vessel, two-vessel, or three-vessel 
disease; angiographic occurrence of no-reflow; use of 
intracoronary drugs to treat NRP in the catheterization 
laboratory (trinitrates, adenosine, verapamil, and sodium 
nitroprusside); acceptable resolution of no-reperfusion; 
use of manual thrombus aspiration; persistent pain after 
the procedure (1 to 10 ); morphine; stent implantation 
(one, two, or three), stent type and dimensions, direct 
stent implantation, balloon pre-dilatation and balloon 
post-dilatation, stent deployment pressure, post-stent 
balloon pressure, intervention performed only with 
balloon (without stent); peak CK-MB, troponin, left 
ventricular ejection fraction; occurrence of procedural 
failure; pre- and post-procedure ST-segment deviation 
(mm); and the occurrence of severe, moderate, and 
minimal bleeding. The following TIMI criteria will 
be used for bleeding events: (1) severe bleeding, if 
intracerebral hemorrhage, or if the clinical picture is 
due to a decrease in Hb > 5 g/dL or hematocrit (Ht) 
> 15%; (2) moderate bleeding if clinical picture of 
hemorrhage with a decrease of Hb of 3-5 g/dL and Ht 
of 9-15%; (3) minimal bleeding, if clinical picture of 
hemorrhage with Hb decrease < 3 g/dL or Ht < 9%; 
moderate and severe thrombocytopenia.
Also during the initial phase of the diagnostic 
cardiac catheterization, peripheral intravenous infusion 
of saline without (placebo) or with tirofiban, according 
to the result of the random allocation of patients to 
one of the two experimental groups will be imple-
mented. Intravenous administration of tirofiban will be 
conducted as follows: loading dose of 25 µg/kg and 
a maintenance dose for 12 hours of 0.15 µg/kg/min. 
Intravenous unfractionated heparin will be administered 
initially at a dose of 100 U/kg body weight when the 
patient is allocated to the infusion of placebo, and 
a dose of 70  U/kg body weight when the infusion is 
tirofiban. This procedure of heparin dose adjustment 
will also be performed in double-blind fashion regarding 
doctors and patients, and it will be the responsibility 
of the nursing staff to maintain the requirements of a 
double-blind study. Acetylsalicylic acid at a loading 
dose of 300 mg, and clopidogrel at an initial dose of 
600 mg will be routinely employed prior to the PPCI 
procedure. The other anti-ischemic drugs (nitrates and 
beta-blockers) will be used as usual. The use of other 
drugs to treat NRP, when angiographically verified 
(nitroglycerin, adenosine, verapamil, and sodium nitro-
prusside), will be left to the PPCI surgeons’ discretion 
in the interventional cardiology laboratory. The use of 
manual thrombus aspiration devices will also be left 
to the surgeons’ discretion.
Sample size calculation 
For sample size calculation, this study will consider 
the estimate based on the literature that NRP in STEMI 
patients undergoing PPCI occurs at an incidence of 
approximately 70%. The study hypothesis to be tested 
is that the incidence reduction will be approximately 
50% in the tirofiban group, that is, a decrease in the 
occurrence of NRP to 35%. In summary:
• Hypothesis: 50% reduction in NRP incidence in 
the active group (with tirofiban);
• Placebo group: estimated incidence of NRP = 
70% represented by P1;
• Tirofiban group: estimated incidence of NRP = 
35% represented by P2;
• Alpha = 5%; corresponds to the probability of 
false positive result (0.05);
• Beta = 20%; corresponds to the probability of 
false negative result (0.20);
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• f (α, β) is the constant resulting from arbitrary 
values conferred to a and b and its value is 7.9, accord-
ing to the statistical table;
With P1 = 70%; P2 = 35%; f (α, β) = 7.9, the 
sample shall be calculated according to the formula: 
 
2
21
2211
)PP(
);,(f)P100(P)P100(P
N
−
βα×−+−×
=
The sample size was calculated, then, as 28 pa-
tients in each branch of the study, for a total number 
of 56 patients.25 Thus:
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CONCLUSIONS
Considering the above-mentioned data, it has po-
tential clinical relevance the systematic investigation of 
the effects of early administration of the low molecular 
weight glycoprotein IIb/IIIa inhibitor tirofiban (the only 
one available in Brazil for clinical use) in the context 
of management of patients with myocardial infarction 
with ST-segment elevation and its association with 
the emergence and consequences of the no-reflow 
phenomenon.
Thus, the purpose of this study is to evaluate whether 
early systematic inhibition of the final common path-
way of platelet aggregation using tirofiban reduces the 
occurrence of no-reflow phenomenon during and after 
primary percutaneous coronary intervention in patients 
with myocardial infarction with ST-segment elevation. 
To achieve this goal, an initial group of approximately 
60 patients will be divided into experimental group 
(tirofiban) and placebo, in randomized order. In an 
unprecedented manner, the occurrence of no-reflow 
phenomenon will be evaluated both 90 minutes after 
the primary percutaneous coronary intervention, as well 
as at 24 h after the procedure, through the successive 
application of angiographic and electrocardiographic 
criteria.
This study may guide future implementation of 
other, more comprehensive, multicenter investigations 
to determine whether the eventual prevention of the 
occurrence of no-reflow phenomenon after treatment by 
primary percutaneous coronary intervention in patients 
with STEMI by administering tirofiban will result in 
survival benefit in the medium and long term.
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